Edwards Lifesciences Corporation (EW) |
|
70.03 0.57 (0.82%)
|
09-26 14:26 |
|
Open: |
69.41 |
Pre. Close: |
69.46 |
|
High:
|
70.97 |
Low:
|
69.29 |
|
Volume:
|
2,227,339 |
Market Cap:
|
42,572(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 1:48:27 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 87.51 One year: 91.82 |
| Support: |
Support1: 68.94 Support2: 57.36 |
| Resistance: |
Resistance1: 74.92 Resistance2: 78.62 |
| Pivot: |
72.86  |
| Moving Average: |
MA(5): 70.26 MA(20): 73.87
MA(100): 83.62 MA(250): 80.88 |
| MACD: |
MACD(12,26): -2.5 Signal(9): -2.3 |
| Stochastic oscillator: |
%K(14,3): 6.8 %D(3): 4 |
| RSI: |
RSI(14): 28 |
| 52-week: |
High: 94.87 Low: 67.12 |
| Average Vol(K): |
3-Month: 3,237 (K) 10-Days: 3,099 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EW ] has closed above bottom band by 17.9%. Bollinger Bands are 5.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
69.79 - 70.28 |
70.28 - 70.66 |
|
Low:
|
67.66 - 68.33 |
68.33 - 68.84 |
|
Close:
|
68.53 - 69.44 |
69.44 - 70.14 |
|
Company Description |
|
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. |
Headline News |
Tue, 26 Sep 2023
Exclusive: Edwards Lifesciences cooperating with EU antitrust ... - Reuters.com
Tue, 26 Sep 2023
Should You Hold Edwards Lifesciences Corp (EW) in Medical Devices Industry? - InvestorsObserver
Tue, 26 Sep 2023
Oppenheimer Upgrades Edwards Lifesciences (EW) - Nasdaq
Mon, 25 Sep 2023
Oak Harvest Investment Services Makes New Investment in ... - MarketBeat
Sun, 24 Sep 2023
Pacer Advisors Inc. Grows Stock Holdings in Edwards Lifesciences ... - MarketBeat
Tue, 19 Sep 2023
FSM Wealth Advisors LLC Takes Position in Edwards Lifesciences ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
608 (M) |
| Shares Float |
602 (M) |
|
% Held by Insiders
|
0.8 (%) |
|
% Held by Institutions
|
85.5 (%) |
|
Shares Short
|
10,750 (K) |
|
Shares Short P.Month
|
9,470 (K) |
Stock Financials |
|
EPS
|
2.2 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
10.48 |
|
Profit Margin (%)
|
24.5 |
|
Operating Margin (%)
|
28.4 |
|
Return on Assets (ttm)
|
11.5 |
|
Return on Equity (ttm)
|
22.3 |
|
Qtrly Rev. Growth
|
11.3 |
|
Gross Profit (p.s.)
|
7.07 |
|
Sales Per Share
|
9.31 |
|
EBITDA (p.s.)
|
2.87 |
|
Qtrly Earnings Growth
|
-23.2 |
|
Operating Cash Flow
|
940 (M) |
|
Levered Free Cash Flow
|
809 (M) |
Stock Valuations |
|
PE Ratio
|
31.84 |
|
PEG Ratio
|
2.9 |
|
Price to Book value
|
6.67 |
|
Price to Sales
|
7.52 |
|
Price to Cash Flow
|
45.28 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
